Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Adv Exp Med Biol ; 501: 333-9, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11787699

RESUMEN

Hemolytic uremic syndrome, a serious complication of Shiga toxin-associated diarrhea, is rare before 6 months of age. Immunologic and nonimmunologic factors present in human milk may partially explain this observation. In prior studies, we have demonstrated that human milk contains Gb3, the receptor for the B subunit of Shiga toxin, and also contains secretory IgA (sIgA) against the toxin. We therefore sought to determine the relative importance of milk glycolipid and toxin-specific sIgA in toxin binding. We studied two populations that differed in their frequency of exposure to Shiga toxin. Human milk samples obtained from healthy donors from Boston and Buenos Aires were separated by centrifugation into aqueous (antibody enriched) and cream (glycosphingolipid enriched) fractions. An emulsion of equal volumes of aqueous phase or cream layer of each sample and purified Shiga toxin was incubated, and the amount of free toxin present in each was determined by enzyme immunoassay. The cream layers bound 85%+/-2 (mean +/- SE) (Argentina milk samples) and 86%+/-1 (Boston milk samples) of Shiga toxin. In contrast, the soluble fraction in samples from Buenos Aires, a population expected to frequently have antibodies to Shiga toxin, bound more toxin (48%+/-2) than did this fraction in samples from Boston, an area where toxin exposure is infrequent (30%+/-3) (P < 0.0001). Toxin-binding lipids present in human milk are biologically active and may contribute to the putative protective effect of human milk. In a population frequently exposed to Shiga toxins (Argentina), protection may be due to both immune (sIgA), and nonimmune (lipid) factors present in human milk. In a population infrequently exposed to Shiga toxins, cream fraction-associated glycolipids represent the major toxin binding activity in human milk.


Asunto(s)
Glucolípidos/metabolismo , Leche Humana/química , Toxina Shiga/metabolismo , Argentina , Boston , Cromatografía Líquida de Alta Presión , Femenino , Glucolípidos/análisis , Glucolípidos/aislamiento & purificación , Humanos
2.
Adv Exp Med Biol ; 501: 457-67, 2001.
Artículo en Inglés | MEDLINE | ID: mdl-11787716

RESUMEN

Lactoferrin is an iron-binding protein found in human mucosal secretions such as milk. A variety of functions have been ascribed to this protein, it appears to contribute to antimicrobial host defense. Still its overall physiological role remains to be defined. We sought to study the role of recombinant human lactoferrin (rhLf) in Shigella infection. Invasion of epithelial cells is essential to the development of bacillary dysentery. Shigella flexneri 5 M90T, a virulent strain, was evaluated in the classic HeLa cell invasion model, in immunoblots, and by transmission electron microscopy, immunofluorescence, and deconvolved microscopy Bacteria not exposed to rhLf were used as controls. We found that rhLf decreased significantly the invasiveness of S. flexneri 5 M90T in a HeLa cell model. The immunoblot data showed that invasion plasmid antigen B (IpaB) was released from the bacteria during incubation with rhLf. Lactoferrin treatment did not directly dissociate the complex of IpaB and IpaC (IpaBC) once the complex had been formed. Furthermore, ferric iron had no effect on release of IpaB. Electron microscopy of rhLf-treated bacteria suggested a reduction in vacuolization of the HeLa cell cytoplasm and decreased number of bacteria within HeLa cells. At 40,000 x magnification the few rhLf-treated Shigella that invaded exhibited a dense ring completely surrounding them. Immunofluorescence and deconvolved microscopy suggested that rhLf-treated bacteria were completely surrounded by a thick layer of actin. The fact that two cell surface functions (invasion and actin-mediated movement) were deranged suggests that rhLf disrupts the integrity of the bacterial outer membrane in which virulence proteins are anchored. The mechanism by which rhLf impairs Shigella invasiveness may be relevant to other enteropathogens that share similar virulence strategies.


Asunto(s)
Lactoferrina/farmacología , Shigella flexneri/efectos de los fármacos , Shigella flexneri/crecimiento & desarrollo , Western Blotting , Células HeLa/microbiología , Humanos , Microscopía Electrónica , Microscopía Fluorescente , Proteínas Recombinantes/farmacología
3.
J Antimicrob Chemother ; 39 Suppl A: 109-13, 1997 May.
Artículo en Inglés | MEDLINE | ID: mdl-9511074

RESUMEN

Many clinical isolates of Enterococcus faecium are resistant to neutrophil-mediated phagocytosis and killing. As antibiotic exposure may alter bacterial surface properties and promote phagocytosis, we used a fluorescence microscopy assay to examine the effect of antibiotic pretreatment on the resistance to phagocytosis of six strains of E. faecium. Using two antimicrobial agents with good in-vitro activity against E. faecium, namely quinupristin/ dalfopristin and sparfloxacin, we found that exposure to quinupristin/dalfopristin at concentrations both below and above the MIC promoted bacterial adherence to neutrophils (PMNs) for all of three strains of vancomycin-susceptible E. faecium, while sparfloxacin was similarly effective in two of these three strains. In contrast, neither antibiotic was effective in promoting PMN adherence for three vancomycin-resistant strains of E. faecium. The variability amongst strains in response to antibiotic exposure suggests that either the mechanisms of resistance to phagocytosis, or its regulation, may be different amongst different strains of E. faecium.


Asunto(s)
Antibacterianos/farmacología , Adhesión Bacteriana/efectos de los fármacos , Enterococcus faecium/efectos de los fármacos , Fluoroquinolonas , Neutrófilos/efectos de los fármacos , Fagocitosis/efectos de los fármacos , Virginiamicina/farmacología , Antiinfecciosos/farmacología , Farmacorresistencia Microbiana , Enterococcus faecium/fisiología , Humanos , Neutrófilos/fisiología , Quinolonas/farmacología
5.
J Antimicrob Chemother ; 39(2): 223-8, 1997 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-9069543

RESUMEN

The analysis of the interaction between antimicrobials and phagocytosis in vitro provides information additional to standard MIC and MBC estimations in predicting in-vivo efficacy. This study investigated the effects of meropenem, a newly available carbapenem, on the activities of human neutrophils against Escherichia coli and Staphylococcus aureus. The results were compared with those obtained with imipenem. Pretreatment of E. coli and S. aureus with meropenem and imipenem sensitized the bacteria to leucocytic killing. In the presence of antibiotics, opsonophagocytic killing of E. coli, but not S. aureus, was synergistically enhanced.


Asunto(s)
Actividad Bactericida de la Sangre/efectos de los fármacos , Escherichia coli/efectos de los fármacos , Neutrófilos/inmunología , Staphylococcus aureus/efectos de los fármacos , Tienamicinas/farmacología , Humanos , Meropenem , Pruebas de Sensibilidad Microbiana
6.
Eur J Clin Microbiol Infect Dis ; 16(1): 13-6, 1997 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-9063667

RESUMEN

Many macrolides have been shown to affect the interaction between bacteria and various immune defense mechanisms, such as chemotaxis, accumulation, and bioactivity within phagocytic cells. The interaction of azithromycin with human polymorphonuclear leukocytes (PMNs) was studied in vitro and compared with the interactions between other macrolides and PMNs. The opsonophagocytic killing of Staphylococcus aureus was synergistically enhanced by azithromycin at concentrations below and above the minimal inhibitory concentration, with a reduction of up to 2.82 log10 cfu/ml with 2 mg/ml of azithromycin. Other macrolides were effective only at subinhibitory concentrations. The beneficial azithromycin-leukocyte interaction may explain azithromycin's efficacy against intracellular pathogens.


Asunto(s)
Antibacterianos/farmacología , Azitromicina/farmacología , Neutrófilos/efectos de los fármacos , Fagocitosis/efectos de los fármacos , Humanos , Neutrófilos/fisiología , Staphylococcus aureus
7.
Antimicrob Agents Chemother ; 40(4): 886-90, 1996 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8849245

RESUMEN

RP 59500, a combination of the streptogramins quinupristin and dalfopristin, and sparfloxacin are new antibiotics with good in vitro activities against Enterococcus faecium, which is an increasingly important nosocomial pathogen with resistance to multiple antimicrobials. Since fluoroquinolones and related macrolides have displayed high intracellular concentrations inside host cells, we evaluated the intracellular activities of these agents inside neutrophils against three strains each of vancomycin-susceptible E. faecium (VSEF) and vancomycin-resistant E. faecium (VREF). At concentrations equal to four times the MIC, RP 59500 and sparfloxacin decreased the number of intracellular VSEF organisms, while both antibiotics were at best bacteriostatic against intracellular VREF strains. At concentrations equal to one-fourth of the MIC, both antibiotics were bacteriostatic against intracellular VSEF strains but were ineffective in inhibiting the growth of VREF strains. Despite their anticipated markedly higher intracellular human neutrophil (PMN) concentrations, RP 59500 and sparfloxacin activities in medium alone were equal to or greater than those inside PMNs against almost all strains. We conclude that the intracellular PMN concentrations of these antibiotics may not be directly related to their intracellular activities in our assay. The reason for the differences in their activities against VSEF versus VREF remains undefined.


Asunto(s)
Antibacterianos/farmacología , Antiinfecciosos/farmacología , Enterococcus faecium/efectos de los fármacos , Fluoroquinolonas , Neutrófilos/microbiología , Quinolonas/farmacología , Virginiamicina/farmacología , Ampicilina/farmacología , Farmacorresistencia Microbiana , Humanos , Pruebas de Sensibilidad Microbiana , Vancomicina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA